



# AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of formula (I-X)



{whereinwherein

R<sup>1</sup> and R<sup>2</sup> are each independently, an acidic group which may be protected, -COOR<sup>A</sup> (wherein R<sup>A</sup> is hydrogen or C1-8 alkyl), -CONR<sup>B</sup>SO<sub>2</sub>R<sup>C</sup> (wherein R<sup>B</sup> is hydrogen or C1-8 alkyl, R<sup>C</sup> is C1-8 hydrocarbon), -SO<sub>2</sub>NR<sup>B</sup>COR<sup>C</sup> (wherein R<sup>B</sup> and R<sup>C</sup> are as described above),




D and E are each independently, a bond or a spacer consisting of 1-8 atom(s) in the main chain,

-D-R<sup>1</sup> is -CO-(CH<sub>2</sub>)<sub>2</sub>-R<sup>1</sup>, -CO-(CH<sub>2</sub>)<sub>3</sub>-R<sup>1</sup>, -CO-(CH<sub>2</sub>)<sub>4</sub>-R<sup>1</sup> or C1-4 alkylene-R<sup>1</sup>,


E is a bond or C1-4 alkylene,

L is an oxygen atom,


W is -O-CH<sub>2</sub>-, -O-(CH<sub>2</sub>)<sub>2</sub>-, -O-(CH<sub>2</sub>)<sub>3</sub>-, -O-(CH<sub>2</sub>)<sub>4</sub>-, -O-(CH<sub>2</sub>)<sub>5</sub>-, -CH<sub>2</sub>-O-, -(CH<sub>2</sub>)<sub>2</sub>-O-, -(CH<sub>2</sub>)<sub>3</sub>-O-, -(CH<sub>2</sub>)<sub>4</sub>-O-, -(CH<sub>2</sub>)<sub>5</sub>-O-, -O-(CH<sub>2</sub>)<sub>3</sub>-O-, -O-(CH<sub>2</sub>)<sub>4</sub>-O-, -O-(CH<sub>2</sub>)<sub>5</sub>-O- or C1-6 alkylene,



(wherein  $R^{110}$  is hydrogen or C1-8 alkyl, and the arrow means that it attaches to



in the ring



ring 1 is a benzene, naphthalene or pyridine ring which may optionally be substituted by a C1-10 straight or branched alkyl, alkenyl or alkynyl group in which optional 1-2 of the carbon atom(s) may be replaced by oxygen, benzene ring, or C5-7 carbocyclic ring,

ring 2 is a benzene, naphthalene, indan or pyridine ring which may optionally be substituted by a group selected from the group consisting of hydroxy, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, fluorine, chlorine, bromine, methoxy, ethoxy, propoxy, butoxy, trifluoromethyl, methylthio, phenyl and pyridyl,

$R^{30}$  is hydrogen, hydroxy, C1-4 alkyl optionally substituted with 1-3 of halogen, C1-4 alkoxy, amino, nitro or halogen,

m is 0 or an integer of 1 to 4, and

$R^3$  is a substituent,

ring A is a cyclic group which may have further substituent(s),

ring B is a cyclic group which may have further substituent(s),

Y and Z are each independently, a carbon atom or a nitrogen atom, and

----- is a single bond or a double bond (provided that Y and/or Z is/are nitrogen

atom(s), the bond is a single bond)), an N-oxide thereof, thereof or a salt thereof, a solvate thereof or a prodrug thereof.

## 2-9. (Cancelled)

**10. (Currently amended)** The compound according to claim 1, which is selected from the group consisting of:

- (1) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (2) 4-(3-carboxypropyl)-8-(((2E)-3-[4-(4-phenylbutoxy)phenyl]-2-propenoyl)amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (3) 4-[8-{[4-(4-phenylbutoxy)benzoyl]amino}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,
- (4) 4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (5) 4-(3-carboxypropyl)-8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (6) 4-(3-carboxypropyl)-8-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (7) (2S)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (8) (2R)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (9) 4-(3-carboxypropyl)-8-({4-[2-(2,3-dihydro-1H-inden-2-yl)ethoxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (10) 4-(3-carboxypropyl)-8-({4-[(5-phenylpentyl)oxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (11) 4-(3-carboxypropyl)-8-({4-[(7-phenylheptyl)oxy]benzoyl}amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,
- (12) 4-(3-carboxypropyl)-8-({4-[(4-methylpentyl)oxy]benzoyl}amino)-3,4-dihydro-2H-

1,4-benzoxazine-2-carboxylic acid,

(13) 4-(3-carboxypropyl)-8-([4-(4-phenoxybutoxy)benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(14) 4-(3-carboxypropyl)-8-([4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(15) 4-(3-carboxypropyl)-8-([4-[4-(4-fluorophenyl)butoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(16) 4-(3-carboxypropyl)-8-([4-[4-(2-methylphenoxy)butoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(17) 4-(3-carboxypropyl)-8-([4-[4-(2-fluorophenoxy)butoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(18) 4-(3-carboxypropyl)-8-([4-[4-(2-chlorophenoxy)butoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(19) 4-(3-carboxypropyl)-8-([4-[4-[2-(trifluoromethyl)phenoxy]butoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(20) 4-(3-carboxypropyl)-8-([4-[3-(2-methylphenoxy)propoxy]benzoyl]amino)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(21) 4-(2-([[(4-methylphenyl)sulfonyl]amino]carbonyl)-8-([4-(4-phenylbutoxy)benzoyl]amino))-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(22) 4-(2-([[(methylsulfonyl)amino]carbonyl]-8-([4-(4-phenylbutoxy)benzoyl]amino))-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(23) 4-(2-([[(benzylsulfonyl)amino]carbonyl]-8-([4-(4-phenylbutoxy)benzoyl]amino))-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid,

(24) 4-(3-carboxypropyl)-8-((E)-2-[4-(4-phenoxybutoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(25) 4-(3-carboxypropyl)-8-((E)-2-[4-(2,3-dihydro-1H-inden-2-ylmethoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(26) 4-(3-carboxypropyl)-8-((E)-2-[4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(27) 4-(3-carboxypropyl)-8-((E)-2-[4-[(5-phenoxypentyl)oxy]phenyl]vinyl)-3,4-dihydro-

2H-1,4-benzoxazine-2-carboxylic acid,

(28) 4-(3-carboxypropyl)-8-((E)-2-{4-[4-(4-methoxyphenoxy)butoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(29) 4-(3-carboxypropyl)-8-((E)-2-{4-[3-(4-fluorophenoxy)propoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(30) 4-(3-carboxypropyl)-8-((E)-2-[4-(3-phenoxypropoxy)phenyl]vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(31) 4-(3-carboxypropyl)-8-((E)-2-{4-[3-(2-chlorophenoxy)propoxy]phenyl}vinyl)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(32) 4-(3-carboxypropyl)-8-{2-[4-(4-phenoxybutoxy)phenyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid,

(33) 4-[8-{2-[4-(4-phenylbutoxy)phenyl]ethyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

(34) 4-[8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl}-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

(35) 4-(2-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)-8-{[4-(4-phenylbutoxy)benzoyl]amino})-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

(36) 4-(2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-8-{(E)-2-[4-(4-phenylbutoxy)phenyl]vinyl})-2,3-dihydro-4H-1,4-benzoxazin-4-yl]butanoic acid,

(37) 4-oxo-4-(8-((4-(4-phenylbutoxy)benzoyl)amino)-2-(1H-tetrazol-5-yl)-2,3-dihydro-4H-1,4-benzoxazin-4-yl)butanoic acid, and

(38) 4-(3-carboxypropyl)-8-((4-(4-phenylbutoxy)benzyl)oxy)-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid.

**11. (Currently amended)** A pharmaceutical composition comprising the compound of formula (I)-(X), an N-oxide thereof, ~~thereof~~ thereof or a salt thereof, ~~a solvate thereof or a prodrug thereof~~ according to claim 1, and a pharmaceutically acceptable agent.

**12-22. (Cancelled)**